Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

NCT00003895 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IA Melanoma
Stage IB Melanoma
Stage IIA Melanoma
Stage IIB Melanoma
Stage IIC Melanoma
Stage IIIA Melanoma
Stage IIIB Melanoma
Stage IIIC Melanoma

Interventions

BIOLOGICAL: HPV 16 E7:12-20
BIOLOGICAL: gp100:209-217(210M)
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)